Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126968101 | 12696810 | 1 | I | 20160826 | 20160826 | 20160830 | 20160830 | PER | US-BAYER-2016-168149 | BAYER | 88.00 | YR | E | F | Y | 54.42000 | KG | 20160830 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126968101 | 12696810 | 1 | PS | CLARITIN | LORATADINE | 1 | Oral | 1 DF, ONCE | CRXFABW | 19658 | 1 | DF | TABLET | 1X | |||||
| 126968101 | 12696810 | 2 | SS | CLARITIN | LORATADINE | 1 | 19658 | TABLET | |||||||||||
| 126968101 | 12696810 | 3 | C | ACETYLSALICYLIC ACID | ASPIRIN | 1 | 0 | ||||||||||||
| 126968101 | 12696810 | 4 | C | CLONAZEPAM. | CLONAZEPAM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126968101 | 12696810 | 1 | Hypersensitivity |
| 126968101 | 12696810 | 2 | Nasopharyngitis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126968101 | 12696810 | Drug effect incomplete | |
| 126968101 | 12696810 | Expired product administered |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126968101 | 12696810 | 1 | 20160826 | 20160826 | 0 |